Safety Study of Post Intravenous tPA Monitoring in Ischemic Stroke "OPTIMIST"


Phase 1/2 Results N/A

Summary of Purpose

Intravenous (IV) tissue plasminogen activator (tPA) is the only FDA-approved therapy for treatment of acute ischemic stroke. In the United States, IV tPA is typically administered in the Emergency Department (ED) for patients presenting with acute ischemic stroke within 4.5 hours of symptom onset. It is current practice that post-tPA patients are monitored in an intensive care unit or intensive care unit...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 22 February 2016.

1 Mar 2014 16 Jan 2014 1 Mar 2017 1 Aug 2017 1 Feb 2016 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Non-Randomized
  • Masking: Open Label
  • Purpose: Health Services Research
  • Endpoint: Safety Study
  • Intervention: Single Group Assignment


  • Victor C Urrutia, MD